Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis

Inclusion Criteria: * Sign the informed consent form or - in case of patients younger than 18 years, the legal responsible must sign the consent; * ≥ 12 years old; * NIS scale score \> 4 points at the randomization visit * Patients with persistent mild to moderate AR, according to the ARIA criteria (see Appendix B), with indication for use budesonide; * Positive skin test for at least one relevant airborne agent; * AR symptoms for at least 2 years; * May undergo a washout period of at least 2 weeks (without using any oral, nasal or inhalant corticosteroid agent; see 6.4). Exclusion Criteria: * Patients with persistent severe allergic rhinitis; * Patients with severe co-morbidities (at the investigator's opinion); * Patients with moderate to severe persistent asthma; * Clinical history of infection of the airways 30 days before the study entry; * Patients with structural changes causing nasal obstruction, such as pronounced nasal septum deviation, nasal polyps or any other type of nasal malformation; * Pregnant women and patients planning to become pregnant during the study period or breastfeeding women; * Patients in need of other drugs to treat the allergic rhinitis, such as anti-immunoglobulin E, allergen-specific immunotherapy, anti-leukotrienes, systemic vasoconstrictors, oral corticosteroids and other inhalant corticosteroids. Patients using allergen-specific immunotherapy during the last year, as well as using anti-leukotrienes and anti-immunoglobulin E during the last month, or even patients using inhalant or oral corticosteroids after V0 will not be enrolled in the study.